We are raising 400K euros from 10 Business Angels made up of radiologists and biologists who are experts in their field. With this new capital and the trust mark from our new shareholders, we are positioning ourselves to become a leading company in AI-based clinical and biological decision support modules.

Early diagnosis for personalized & precise follow-up

The year after our creation, we won our first prize, from the French Audiology Society 2022, for our LAbyrInth technology. Its aim is to diagnose inner ear abnormalities, invisible to radiologists with the naked eye, as early as possible. The aim is to implement treatment early enough to avoid irreversible damage to the patient.

By 2023, our team has already doubled in size, and is still growing. On the agenda: new premises, new projects and new recruits. Our DementIA software is now on the road to CE marking. We are continuing to develop other clinical and biological decision support modules based on digital twins and generative artificial intelligence.